Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Epizyme nets $71.7mm in IPO

Executive Summary

Cancer epigenetics company Epizyme Inc. has completed its IPO, netting $71.7mm through the sale of 5.1mm shares at $15, the high end of the company’s anticipated $13-15 range. All four biotechs, including Epizyme, that filed for their IPOs in April have completed their offerings: anticoagulant developer Portola Pharmaceuticals Inc. brought in $131mm; immunology firm Receptos Inc. raised $68.3mm; and plasma therapeutics developer Kamada Inc. netted $48mm.
Deal Industry
  • Pharmaceuticals
  • In Vitro Diagnostics
    • Molecular Diagnostics & Genetic Testing
  • Biotechnology
    • Pharmacogenetics-Pharmacogenomics
Deal Status
  • Final
Deal Type
  • Financing
    • IPO

Related Companies